A Golden Age of Bladder Cancer Drug Development
Checkpoint inhibitors and FGFR inhibitors have led to FDA approvals and improved outcomes for metastatic urothelial carcinoma.
Recent years have seen an explosive rate of transformative advances in both pre‑clinical and clinical urothelial carcinoma research. With the public dissemination of comprehensive molecular data from The Cancer Genome Atlas (TCGA) urothelial carcinoma cohort, the global urothelial carcinoma research community now has the initial roadmap of the key biological themes that drive carcinogenesis, growth, invasion, and metastasis.
The rapid approval of multiple immuno‑checkpoint and targeted therapies has shifted bladder cancer from a disease with limited treatment options to one with an expanding armamentarium, improving survival prospects for metastatic patients and stimulating further research into new therapeutic avenues.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.